MBOT - NASDAQ
Microbot Medical Inc.
$1.97
-0.51%Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
At a Glance
Live SnapshotNo Revenue Data
MBOT has not reported any revenue values in the available annual periods.
Microbot Medical Inc. Profit Bridge
Profitability Analysis
Microbot Medical Inc. Income Statement
MBOT • NASDAQ
| Microbot Medical Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 117K | 1M | 1.2M | 1.4M | 1.2M | 1.4M | 992.9K | 231.7K | 56.7K | 92.9K | |
GROSS PROFIT | ||||||||||||||||||||
(47K) | (91K) | (106K) | (0.0) | (0.0) | (0.0) | (84K) | (54K) | (21K) | (10K) | (17K) | -391.0 | (316.6K) | (263.2K) | (214.8K) | (168.4K) | (261.4K) | (1.2M) | (1.2M) | (1M) | |
-47K | -91K | -106K | 0.0 | 0.0 | 0.0 | -84K | -54K | -21K | -10K | 117K | 1M | 1.2M | 1.1M | 1M | -262K | -963K | -955K | -1.1M | -952K | |
OPERATING INCOME | ||||||||||||||||||||
(14.7M) | (11.5M) | (9.7M) | (13.3M) | (11.4M) | (9.1M) | (7.2M) | (7.2M) | (5.3M) | (9.6M) | (915K) | (30.6M) | (27.9M) | (22.1M) | (29.1M) | (30.6M) | (27.8M) | (24.9M) | (26.7M) | (19.7M) | |
(8.5M) | (5M) | (4.1M) | (5.6M) | (5.4M) | (5.9M) | (4.4M) | (4.7M) | (4.2M) | (8.8M) | (9.3M) | (93.8K) | (70.0) | (6.7M) | (8.2M) | (9.4M) | (9.5M) | (8.3M) | (6.8M) | (6.1M) | |
(6.3M) | (6.6M) | (5.7M) | (7.7M) | (6.2M) | (3.4M) | (3M) | (2.9M) | (1.3M) | (1.1M) | (823K) | (21.5M) | (19.4M) | (15.8M) | (19.9M) | (21M) | (19.9M) | (17.8M) | (19.9M) | (13.6M) | |
-14.7M | -11.6M | -9.9M | -13.3M | -11.4M | -9.1M | -7.2M | -7.2M | -5.3M | -9.6M | -36.7M | -30.9M | -805.0 | -22.2M | -27.1M | -29.1M | 29.4M | 26.7M | 28.6M | 21.4M | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (80K) | (103K) | (0.0) | (238K) | (334K) | (506.3K) | (1.3M) | (1.2M) | (50.2K) | (71.4K) | (93.4K) | (110.8K) | (109.8K) | (123.6K) | (143K) | |
1.3M | 182K | 228K | 54K | 44K | -79.9K | -103K | 0.0 | 0.0 | 0.0 | -499K | -1.3M | -1.2M | -34.6K | -57.4K | -66.7K | -43.5K | 693.3K | 2.3M | 2.3M | |
(0.0) | -91K | -106K | -36K | -206K | -195K | -178K | -476K | -213K | -249K | -230K | -458K | -254.8K | (93.2K) | (942.1K) | (222K) | -58.1M | -52.6M | -56.4M | -42M | |
1.6M | 182K | -885K | 113K | 44K | -80K | -7K | -16K | -2.3M | -28K | -6K | -1.4M | 2.1M | -6.1M | 5.8M | 3.9M | -56.4M | -55.8M | -53.6M | -21.4M | |
-13.1M | -11.4M | -10.7M | -13.2M | -11.3M | -9.2M | -7.2M | -7.3M | -7.6M | -9.7M | -36.4M | -32.3M | -26M | -28M | -21.3M | -25.2M | -27M | -29.1M | -25M | -18.9M | |
NET INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (20K) | (0.0) | (0.0) | (0.0) | -337.0 | (159.0) | (83.9K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -2.4M | |
-13.1M | -11.4M | -10.7M | -13.2M | -11.3M | -9.2M | -7.2M | -7.3M | -7.6M | -9.7M | -36.4M | -32.7M | -26.4M | -28.5M | -21.3M | -25.2M | -27M | -29.1M | -25M | -18.9M |
SEC Filings
MBOT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | June 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 26, 2026 | May 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 15, 2026 | May 15, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 22, 2026 | April 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 14, 2026 | April 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 13, 2026 | April 13, 2026 | 2026 |
Related Guides
Continue your MBOT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.